Novartis has divested, restructured, or mothballed 24 manufacturing plants since 2010 but says its new NBS cost-saving business will not focus on streamlining and consolidating sites.
AstraZeneca has partnered to use the CRISPR genome editing technique across its discovery programmes in a move that puts it on a collision course with French Biotech, Cellectis.
New hepatitis C drugs produced by Gilead, Janssen and AbbVie contributed to a first quarter spike in revenue for AmeriSourceBergen’s Pharmaceutical Distribution business.
The World Health Organisation's regional director for Africa makes plans to tackle Ebola, plus more from AstraZeneca, TransCelerate, AmerisourceBergen, and more.
Provectus Biopharmacetuicals is seeking an Indian patent and partner for PV-10 and says it is 'more than a match' for skin cancer competitors like Merck & Co and Bristol-Myers Squibb.
